Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers

A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types

(2011) Stephen Jamieson et al.   BIOCHEMICAL JOURNAL

Platinums sensitize human epithelial tumor cells to lymphotoxin α by inhibiting NF-κB-dependent transcription

(2010) Yijun Shen et al.   CANCER BIOLOGY & THERAPY

Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression

(2010) Gail T. McDonald et al.   EXPERIMENTAL CELL RESEARCH

Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

(2009) Michael A. Bookman et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting the PI3K p110  Isoform Inhibits Medulloblastoma Proliferation, Chemoresistance, and Migration

(2008) A. S. Guerreiro et al.   CLINICAL CANCER RESEARCH

PTEN-deficient cancers depend on PIK3CB

(2008) S. Wee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phosphoinositide 3-Kinase p110  Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development

(2008) E. Ciraolo et al.   Science Signaling

PI3K/PTEN signaling in tumorigenesis and angiogenesis

(2007) Bing-Hua Jiang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS